BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35482084)

  • 21. Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome.
    Yarom N; Yahalom R; Shoshani Y; Hamed W; Regev E; Elad S
    Osteoporos Int; 2007 Oct; 18(10):1363-70. PubMed ID: 17598065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.
    Van Poznak CH; Unger JM; Darke AK; Moinpour C; Bagramian RA; Schubert MM; Hansen LK; Floyd JD; Dakhil SR; Lew DL; Wade JL; Fisch MJ; Henry NL; Hershman DL; Gralow J
    JAMA Oncol; 2021 Feb; 7(2):246-254. PubMed ID: 33331905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
    Ulmner M; Jarnbring F; Törring O
    J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study.
    Park JH; Cho S; Kim SJ; Jeong TD; Mun YC; Kim JW
    Osteoporos Int; 2022 Feb; 33(2):367-377. PubMed ID: 34471956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced osteonecrosis of the jaw: the state of the art.
    Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D
    Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
    de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients.
    Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S
    J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
    Hoefert S; Schmitz I; Tannapfel A; Eufinger H
    Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review.
    Crépin S; Laroche ML; Sarry B; Merle L
    Eur J Clin Pharmacol; 2010 Jun; 66(6):547-54. PubMed ID: 20437036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience.
    Vandone AM; Donadio M; Mozzati M; Ardine M; Polimeni MA; Beatrice S; Ciuffreda L; Scoletta M
    Ann Oncol; 2012 Jan; 23(1):193-200. PubMed ID: 21427065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osteonecrosis of the jaw among patients with cancer treated with denosumab or zoledronic acid: Results of a regulator-mandated cohort postauthorization safety study in Denmark, Norway, and Sweden.
    Ehrenstein V; Heide-Jørgensen U; Schiødt M; Akre O; Herlofson BB; Hansen S; Larsson Wexell C; Nørholt SE; Tretli S; Kjellman A; Glennane A; Lowe KA; Sørensen HT
    Cancer; 2021 Nov; 127(21):4050-4058. PubMed ID: 34310704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
    Van Poznak C; Estilo C
    Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
    O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
    J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
    Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
    Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
    Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
    Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
    Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
    Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.
    Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA
    Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.